Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.

Tumor Necrosis Factor (TNF) blocking agents are associated with lower risk for Alzheimer’s disease in patients with rheumatoid arthritis and psoriasis

Open access

Published version of a preprint

Abstract

This large, retrospective case-control study of electronic health records from 56 million unique adult patients examined whether or not treatment with a Tumor Necrosis Factor (TNF) blocking agent is associated with lower risk for Alzheimer's disease (AD) in patients with rheumatoid arthritis (RA), psoriasis, and other inflammatory diseases which are mediated in part by TNF and for which a TNF blocker is an approved treatment. The analysis compared the diagnosis of AD as an outcome measure in patients receiving at least one prescription for a TNF blocking agent (etanercept, adalimumab, and infliximab) or for methotrexate. Adjusted odds ratios (AORs) were estimated using the Cochran-Mantel-Haenszel (CMH) method and presented with 95% confidence intervals (CIs) and p-values. RA was associated with a higher risk for AD (Adjusted Odds Ratio (AOR) = 2.06, 95% Confidence Interval: (2.02-2.10), P-value <0.0001) as did psoriasis (AOR = 1.37 (1.31-1.42), P <0.0001), ankylosing spondylitis (AOR = 1.57 (1.39-1.77), P <0.0001), inflammatory bowel disease (AOR = 2.46 (2.33-2.59), P < 0.0001), ulcerative colitis (AOR = 1.82 (1.74-1.91), P <0.0001), and Crohn's disease (AOR = 2.33 (2.22-2.43), P <0.0001). The risk for AD in patients with RA was lower among patients treated with etanercept (AOR = 0.34 (0.25-0.47), P <0.0001), adalimumab (AOR = 0.28 (0.19-0.39), P < 0.0001), or infliximab (AOR = 0.52 (0.39-0.69), P <0.0001). Methotrexate was also associated with a lower risk for AD (AOR = 0.64 (0.61-0.68), P <0.0001), while lower risk was found in patients with a prescription history for both a TNF blocker and methotrexate. Etanercept and adalimumab also were associated with lower risk for AD in patients with psoriasis: AOR = 0.47 (0.30-0.73 and 0.41 (0.20-0.76), respectively. There was no effect of gender or race, while younger patients showed greater benefit from a TNF blocker than did older patients. This study identifies a subset of patients in whom systemic inflammation contributes to risk for AD through a pathological mechanism involving TNF and who therefore may benefit from treatment with a TNF blocking agent.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0229819

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 A screen shot of cohort identification using the IBM Watson Health Explorys Cohort Discovery fast search tool. This example selects female White patients with age > 65 years with a diagnosis code for dementia and a prescription for etanercept.
Fig 1 A screen shot of cohort identification using the IBM Watson Health Explorys Cohort Discovery fast search tool. This example selects female White patients with age > 65 years with a diagnosis code for dementia and a prescription for etanercept.CC BY · PubMed Central
Fig 2 Cumulative age distribution of patients with a diagnosis code for rheumatoid arthritis, dementia or Alzheimer’s disease.
Fig 2 Cumulative age distribution of patients with a diagnosis code for rheumatoid arthritis, dementia or Alzheimer’s disease.CC BY · PubMed Central
Fig 3 a. Adjusted Odds Ratio (AOR) for a diagnosis of Alzheimer’s disease associated with a diagnosis for an inflammatory disease as compared to the non-inflammatory disease group. Abbreviations: RA -rheumatoid arthritis, AS -ankylosing spondylitis, PA -psoriatic arthritis, IBD -inflammatory bowel disease, UC -ulcerative colitis, Crohn’s -Crohn’s disease. b Adjusted Odds Ratios (AORs) for a diagnosis of Alzheimer’s disease associated with a diagnosis for rheumatoid arthritis as compared to the non-inflammatory disease group, further adjusting for BMI, smoking status, or alcohol use. The added covariate is presented in column 2. We present both adjusted and stratified AOR for each covariate.
Fig 3 a. Adjusted Odds Ratio (AOR) for a diagnosis of Alzheimer’s disease associated with a diagnosis for an inflammatory disease as compared to the non-inflammatory disease group. Abbreviations: RA -rheumatoid arthritis, AS -ankylosing spondylitis, PA -psoriatic arthritis, IBD -inflammatory bowel disease, UC -ulcerative colitis, Crohn’s -Crohn’s disease. b Adjusted Odds Ratios (AORs) for a diagnosis of Alzheimer’s disease associated with a diagnosis for rheumatoid arthritis as compared to the non-inflammatory disease group, further adjusting for BMI, smoking status, or alcohol use. The added covariate is presented in column 2. We present both adjusted and stratified AOR for each covariate.CC BY · PubMed Central
Fig 4 Adjusted Odds Ratio (AOR) for a diagnosis code of dementia associated with a diagnosis for an inflammatory disease as compared to the non-inflammatory disease group. Abbreviations: RA -rheumatoid arthritis, AS -ankylosing spondylitis, PA -psoriatic arthritis, IBD -inflammatory bowel disease, UC -ulcerative colitis, Crohn’s -Crohn’s disease.
Fig 4 Adjusted Odds Ratio (AOR) for a diagnosis code of dementia associated with a diagnosis for an inflammatory disease as compared to the non-inflammatory disease group. Abbreviations: RA -rheumatoid arthritis, AS -ankylosing spondylitis, PA -psoriatic arthritis, IBD -inflammatory bowel disease, UC -ulcerative colitis, Crohn’s -Crohn’s disease.CC BY · PubMed Central
Fig 5 Adjusted Odds Ratio (AOR) showing inverse risk associations between Alzheimer’s disease or a diagnosis of dementia and prescription history of a TNF blocker (exclude certolizumab pegol and golimumab) or methotrexate compared to the no-drug group in patients with a diagnosis of rheumatoid arthritis with a prescription. The analysis excluded patients with a prescription history of a TNF blocker and methotrexate.
Fig 5 Adjusted Odds Ratio (AOR) showing inverse risk associations between Alzheimer’s disease or a diagnosis of dementia and prescription history of a TNF blocker (exclude certolizumab pegol and golimumab) or methotrexate compared to the no-drug group in patients with a diagnosis of rheumatoid arthritis with a prescription. The analysis excluded patients with a prescription history of a TNF blocker and methotrexate.CC BY · PubMed Central
Fig 6 Adjusted Odds Ratio (AOR) showing inverse associations between Alzheimer’s disease or a diagnosis of dementia and prescription history of methotrexate and a TNF blocker compared to the methotrexate and no-TNF blocker group in patients with a diagnosis of rheumatoid arthritis.
Fig 6 Adjusted Odds Ratio (AOR) showing inverse associations between Alzheimer’s disease or a diagnosis of dementia and prescription history of methotrexate and a TNF blocker compared to the methotrexate and no-TNF blocker group in patients with a diagnosis of rheumatoid arthritis.CC BY · PubMed Central
Fig 7 Adjusted Odds Ratio (AOR) showing inverse associations between Alzheimer’s disease or a diagnosis of dementia and prescription history of a TNF blocker (exclude certolizumab pegol and golimumab) or methotrexate compared to the no-drug group in patients with a diagnosis of psoriasis.
Fig 7 Adjusted Odds Ratio (AOR) showing inverse associations between Alzheimer’s disease or a diagnosis of dementia and prescription history of a TNF blocker (exclude certolizumab pegol and golimumab) or methotrexate compared to the no-drug group in patients with a diagnosis of psoriasis.CC BY · PubMed Central
Fig 8 Adjusted Odds Ratio (AOR) showing inverse associations between Alzheimer’s disease or a diagnosis of dementia and prescription history of a TNF blocker in patients with a diagnosis of psoriasis adjusting for methotrexate prescription status.
Fig 8 Adjusted Odds Ratio (AOR) showing inverse associations between Alzheimer’s disease or a diagnosis of dementia and prescription history of a TNF blocker in patients with a diagnosis of psoriasis adjusting for methotrexate prescription status.CC BY · PubMed Central
Fig 9 Effect of age, gender and race on risk for a diagnosis of dementia in rheumatoid arthritis patients treated with etanercept. Young patients (18–65 years) showed greater benefit than did older patients (over 65 years). The effect of gender and race was not significant.
Fig 9 Effect of age, gender and race on risk for a diagnosis of dementia in rheumatoid arthritis patients treated with etanercept. Young patients (18–65 years) showed greater benefit than did older patients (over 65 years). The effect of gender and race was not significant.CC BY · PubMed Central
Fig 10 Crude Odds Ratios (OR) and Adjusted Odds Ratios (AOR) based on insurance status (Medicaid versus no-Medicaid, or private versus no-private insurance) in patients with a diagnosis code for dementia and rheumatoid arthritis.
Fig 10 Crude Odds Ratios (OR) and Adjusted Odds Ratios (AOR) based on insurance status (Medicaid versus no-Medicaid, or private versus no-private insurance) in patients with a diagnosis code for dementia and rheumatoid arthritis.CC BY · PubMed Central
Fig 11 Comparison of the risk for a diagnosis of Alzheimer’s disease or dementia in patients with a diagnosis of rheumatoid arthritis or psoriasis with a prescription history for etanercept, adalimumab, or infliximab who were not prescribed methotrexate against the general population.
Fig 11 Comparison of the risk for a diagnosis of Alzheimer’s disease or dementia in patients with a diagnosis of rheumatoid arthritis or psoriasis with a prescription history for etanercept, adalimumab, or infliximab who were not prescribed methotrexate against the general population.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 66 references

Cited by

See all 157

Metadata

Authors
Zhou, M., Xu, R., Kaelber, D. C., & Gurney, M. E.
Affiliations
  • Case Western Reserve University (US)
  • MetroHealth (US)
  • Tetra Therapeutics (United States) (US)
Corresponding author
  • Xu, Rong
  • Gurney, Mark E.
Venue
PLOS ONE
Published
2020-03-23
Volume
15
Issue
3
Pages
e0229819
ISSN
1932-6203 (ISSN-L)
OpenAlex
W3012855465
Cited by
157
References
66
Citations by year
2026: 14 · 2025: 21 · 2024: 23 · 2023: 27 · 2022: 38 · 2021: 21 · 2020: 13
FWCI
18.65
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • medRxiv (acceptedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (DP2HD084068)
  • National Institute on Aging (R01 AG057557, R01 AG061388, R56 AG062272)
  • American Cancer Society (RSG-16-049-01 - MPC)
  • National Institute of Mental Health (MH091791, MH107077)
Topics
  • Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
Alzheimer's disease, TNF-alpha inhibitors, rheumatoid arthritis, psoriasis, ankylosing spondylitis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, etanercept, adalimumab, infliximab, methotrexate, anti-TNF therapy, neurodegeneration risk, electronic health records, pharmacoepidemiology
MeSH terms
Etanercept, Adalimumab, Infliximab, Tumor Necrosis Factor Inhibitors, Adolescent, Adult, Aged, Alzheimer Disease, Arthritis, Rheumatoid, Colitis, Ulcerative, Female, Humans, Male, Methotrexate, Middle Aged, Retrospective Studies, Risk, Arthritis, Psoriatic, Case-Control Studies, Antirheumatic Agents, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tumor Necrosis Factor (TNF) blocking agents are associated with lower risk for Alzheimer’s disease in patients with rheumatoid arthritis and psoriasis. https://app.cochat.ai/papers/10.1371/journal.pone.0229819
The paper
Zhou, M., Xu, R., Kaelber, D. C., & Gurney, M. E. (2020). Tumor Necrosis Factor (TNF) blocking agents are associated with lower risk for Alzheimer’s disease in patients with rheumatoid arthritis and psoriasis. PLOS ONE. https://doi.org/10.1371/journal.pone.0229819

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.